64th American Society of Hematology Annual Meeting and Exposition (ASH 2022)
New Orleans, Louisiana, US 10 December 2022 - 13 December 2022
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
06 Feb 2023
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
20 Jan 2023
PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib
The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.